109 related articles for article (PubMed ID: 33705152)
1. Synergistic Therapy for Cervical Cancer by Codelivery of Cisplatin and JQ1 Inhibiting Plk1-Mutant Trp53 Axis.
Wang Y; Shen N; Li S; Yu H; Wang Y; Liu Z; Han L; Tang Z
Nano Lett; 2021 Mar; 21(6):2412-2421. PubMed ID: 33705152
[TBL] [Abstract][Full Text] [Related]
2. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
3. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
4. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
5. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
7. Effects of BRD4 inhibitor JQ1 on the expression profile of super-enhancer related lncRNAs and mRNAs in cervical cancer HeLa cells.
Zheng J; Huang B; Xiao L; Wu M
PeerJ; 2024; 12():e17035. PubMed ID: 38410799
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
9. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
10. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
11. BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Ni M; Li J; Zhao H; Xu F; Cheng J; Yu M; Ke G; Wu X
Oncogene; 2021 Apr; 40(15):2711-2724. PubMed ID: 33712705
[TBL] [Abstract][Full Text] [Related]
12. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
13. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.
Shi F; Su J; Liu Z; Wang J; Wang T
J Cell Biochem; 2019 Sep; 120(9):15018-15026. PubMed ID: 31017720
[TBL] [Abstract][Full Text] [Related]
14. Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation.
Leekha A; Gurjar BS; Tyagi A; Rizvi MA; Verma AK
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2503-2514. PubMed ID: 27613187
[TBL] [Abstract][Full Text] [Related]
15. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Zhang L; Tong Y; Zhang X; Pan M; Chen S
Drug Des Devel Ther; 2015; 9():5851-62. PubMed ID: 26586936
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of a cisplatin-resistant human cervical cancer cell line].
Chen XL; Wang H; Zhang XM; Liu HQ; Liu SL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 43(2):151-5. PubMed ID: 22650020
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
19. Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
Rataj O; Haedicke-Jarboui J; Stubenrauch F; Iftner T
Int J Cancer; 2019 May; 144(9):2330-2338. PubMed ID: 30421459
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake.
Piro G; Roca MS; Bruzzese F; Carbone C; Iannelli F; Leone A; Volpe MG; Budillon A; Di Gennaro E
Mol Cancer Ther; 2019 Aug; 18(8):1405-1417. PubMed ID: 31189612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
